Probi

Name

Probi

Legal name

Probi AB

Website

https://probi.com

Company type

Private

Founded year

1991

Operating status

Operating

Headcount range

101–250 employees

Ownership category

akta.pro rank

Product category

Probiotic Ingredients and Biotic Solutions

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Probiotics (Strains, Spore-Formers, Synbiotic Components) (AFAJAKAE)

akta.pro secondary industries

Probiotics (Human & Animal Strains, Spore-Formers, Synbiotic Bases) (AFAJAJAE), Probiotic/Direct-Fed Microbial (DFM) Premixes (AFADAGAG), Nutraceuticals & Functional Ingredients for Animal Diets (Probiotics, Omega-3, Joint, GI) (HLAMAHAH), Probiotic, Prebiotic & Gut-Health Foods Manufacturing (Fermented Functional Foods, Synbiotics) (AFAKAJAH), Probiotic/Prebiotic Functional Beverage Production (Non-Fermented) (AFAFAFAE)

Keywords

• Probiotic ingredients
• Biotech research
• Clinical strain development
• Nutraceutical solutions
• Functional food ingredients

Headquarters

HQ city

Lund

HQ country

Sweden

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Probiotic ingredients and strains: B2B sales of proprietary probiotic strains to manufacturers of dietary supplements, functional foods, beverages, and pet nutrition products. Revenue generated through ingredient sales and distribution agreements.
2. Finished product distribution: Since April 2023, Probi has its own distribution in Sweden with control over brand and distribution strategy for consumer products.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Probi develops, manufactures, and supplies proprietary probiotic and biotic strains (including LP299V®, BLIS K12™, BLIS M18™, HEAL9®, 8700:2) and branded finished biotic solutions targeting digestive, immune, oral, women's, metabolic, mental, pediatric, sports, and healthy aging applications. The company sells these ingredients and branded solutions on a B2B basis to dietary supplement, functional food and beverage, and pet nutrition manufacturers across more than 40 markets, supported by 35+ years of clinical research and proprietary delivery/stability technologies (BIO-tract®, Probi LiveBac®).

Product overview

Probi is a global biotics solutions company focused on researching, manufacturing, and delivering probiotic and biotic strains, solutions, and technologies for supplements and functional food. The company's portfolio includes clinically studied probiotic strains such as LP299V® (the world's most clinically studied L. plantarum strain), BLIS K12™, BLIS M18™, HEAL9®, and 8700:2. Probi offers branded health solutions including Probi FerroSorb® (iron absorption), Probi® Osteo (bone health), Probi Digestis® (digestive health), and Probi Defendum® (immune health), along with proprietary technologies BIO-tract® and Probi LiveBac® for enhanced delivery and stability. Products are targeted across key health areas: Mental Health, Digestive Health, Immune Health, Metabolic Health, Women's Health, Healthy Aging, Kids' Health, Oral Health, and Sports and Active Nutrition. Application areas include Dietary Supplements, Food & beverages, Probiotics for pets, Probiotic spores, and Postbiotic. Probi serves over 40 markets worldwide and has been part of Symrise AG since 2025.

Differentiator

Problem solved

Functional benefit

Brands

• Probi Digestis®: Registered trademark for probiotic products targeting digestive health
• Probi Defendum®
• Probi FerroSorb®
• Probi® Osteo
• BIO-tract®
• Probi LiveBac®
• LP299V®
• BLIS® by Probi®

Products and services

• LP299V® probiotic strain Lactiplantibacillus plantarum 299v, the world's most clinically studied probiotic strain, proven safe for children from one year of age. It helps maintain a healthy intestinal flora by adhering to the intestinal lining and outcompeting unfriendly bacteria, and has a unique capacity to increase iron absorption. Sold as a B2B ingredient to dietary supplement, food and beverage, and pet nutrition manufacturers.
• BLIS K12™ A specific strain of Streptococcus salivarius (BLIS K12™) that supports optimal ear, nose, and throat (ENT) immunity, helps maintain fresh breath, and may reduce halitosis when combined with good oral hygiene. Distributed exclusively by Probi in the US, Canada, and select EMEA markets for human and pet health.
• BLIS M18™ A specific strain of Streptococcus salivarius (BLIS M18™) that supports healthy teeth, gums, and overall oral health when used regularly in conjunction with good dental hygiene. Distributed exclusively by Probi in the US, Canada, and select EMEA markets for human and pet health.
• HEAL9® probiotic strain Immune-supporting probiotic strain (HEAL9®) that supports upper respiratory health and immune function in children. Sold as a B2B ingredient to dietary supplement manufacturers.
• 8700:2 probiotic strain
• Probi FerroSorb® Probiotic solution targeting iron absorption. When combined with iron, LP299V® acts to increase iron absorption and reduce gastrointestinal side effects commonly associated with traditional iron supplements. Aimed at women's health, particularly iron deficiency. Awarded multiple NutraIngredients Awards in 2025 for outstanding innovation in women's health.
• Probi® Osteo
• Probi Digestis®
• Probi Defendum®
• Probi Sweden consumer distribution Since April 2023, Probi has operated its own consumer product distribution in Sweden, controlling brand and distribution strategy for finished probiotic consumer products in the Swedish market. Represents a small consumer-direct channel alongside the company's primary B2B business.

Quantifiable outcome

• LP299V® is the world's most clinically studied L. plantarum strain, with first clinical study dating back to 2006
• +2 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• BLIS TechnologiescoreChannel Partner/ Reseller/ Distributor · 28 October 2025Probi has a long-term strategic partnership with BLIS Technologies, renewed in October 2025, granting Probi exclusive distribution rights for probiotic strains BLIS K12™ and BLIS M18™ in the US, Canada, and select EMEA markets for both human and pet health. This partnership positions Probi at the forefront of oral health innovation and extends exclusivity to include pet nutrition.
• Symrise AGcoreStrategic or Co-development Partner · 1 January 2025Probi became part of Symrise AG in 2025 following an acquisition. Symrise established a new Care & Wellness Division within its Scent & Care segment, integrating cosmetic ingredients, health actives, and biotics capabilities including expertise from the Probi acquisition. This move strengthens both innovation capabilities and global reach of Probi, delivering science-based solutions across topical, ingestible, and 'inside-out' beauty concepts.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Novonesis (formerly Chr. Hansen): Global leader in microbial and fermentation-based solutions including a broad probiotic cultures portfolio serving dietary supplement, dairy, and infant nutrition manufacturers. Directly comparable to Probi as a B2B supplier of clinically-documented probiotic strains across overlapping health areas and customer segments.
• Lallemand Health Solutions: Specializes in probiotic strain development and B2B supply for human and pet health applications with documented clinical evidence. Directly competes with Probi's LP299V®-led portfolio across digestive, immune, and women's health segments with similar go-to-market and clinical-substantiation approach.
• BioGaia: Swedish probiotic company built around proprietary Lactobacillus reuteri strains sold B2B to supplement and infant formula manufacturers worldwide. Closely comparable in business model (proprietary strain IP, clinical evidence, global B2B distribution) and overlaps Probi in pediatric, oral, and digestive health.
• Winclove Probiotics: Dutch probiotic company specializing in multi-strain formulations for specific health indications, sold B2B to supplement and F&B manufacturers globally. Directly comparable in business model and clinical-evidence-led approach, with overlapping focus on women's, digestive, and immune health applications.

Broad incumbents

• Lesaffre: Global fermentation specialist producing yeast, bacteria, and biotics ingredients for food, nutrition, and health applications. Comparable as a larger, broader incumbent in the microbial ingredient space competing with Probi across F&B, supplement, and animal nutrition applications.
• ADM (Animal Nutrition & Health): Global nutrition and ingredient platform with a significant probiotics portfolio (including the Protexin acquisition) serving human and animal health customers. Comparable as a diversified incumbent leveraging scale, distribution, and cross-selling to compete with Probi in supplements and pet nutrition.
• IFF Health & Biosciences (formerly DuPont Nutrition & Biosciences): Major ingredient and bioscience platform with probiotic strain offerings (HOWARU®) for dietary supplements, F&B, and animal nutrition. Comparable as a large-scale incumbent with broader portfolio reach competing with Probi across many of the same B2B health applications.
• DSM-Firmenich: Global health, nutrition, and beauty ingredients company with a probiotics portfolio targeting digestive, immune, and women's health applications. Comparable to Probi at the B2B ingredient level across dietary supplements and F&B, with greater scale and broader category reach.
• Kerry Group: Global taste and nutrition ingredients platform that acquired Ganeden, adding clinically-substantiated probiotic strains to its B2B offering. Comparable to Probi in supplying F&B and supplement manufacturers, with broader ingredients portfolio and deeper food industry customer relationships.

Emerging players

• AB Biotics (AB Biotics Health): Spain-based probiotic company developing proprietary strains for mental health, women's health, and sports nutrition, sold B2B to supplement brands. Comparable to Probi as a clinical-evidence-driven probiotic company targeting overlapping health areas and customer segments, though smaller in scale and geographic reach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xinstagram.com/probi.official
• Facebookfacebook.com/probisverige
• LinkedInlinkedin.com/company/probi-ab
• Instagraminstagram.com/probi.official

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Probi